Clinical Trial Update: An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma [Phase 3]

View source ↗

Summary

Phase 3 efficacy trial comparing Symbicort (budesonide/formoterol) pMDI to budesonide HFA pMDI in ICS-dependent asthma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Pulmicort HFA (budesonide)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2012-08-27